Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 542 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06482801RecruitingPhase 2
Immunotherapy combo for newly treated liver cancer
This trial tests a combination of immunotherapy drugs given directly into the liver’s blood supply as a first treatment for liver cancer. It aims to see if this approach can shrink tumors and improve outcomes for people with relatively preserved liver function.
GuangzhouAges 18–75 - NCT07135453RecruitingPhase 4
Pneumonia vaccine study for healthy adults
This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.
Birmingham, AlabamaAges 18 years+ - NCT06498752RecruitingPhase 2
MRD-guided consolidation therapy after radiation for esophageal cancer
This trial looks at whether a treatment guided by a blood test (MRD) after radiation can help prevent esophageal cancer from coming back. It tests a personalized approach to decide if more treatment is needed.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06523296Recruiting
Antibodies and thinking problems in myasthenia or Alzheimer's
This study looks at whether certain antibodies are linked to memory and thinking problems in people with myasthenia gravis or Alzheimer's disease. It involves a one-time use of leftover spinal fluid from a previous diagnostic test.
Nice, Alpes MaritimesAges 18 years+ - NCT06532006RecruitingPhase 3
HLX22 plus trastuzumab and chemo for HER2+ stomach cancer
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
Anaheim, CaliforniaAges 18 years+ - NCT06541626Recruiting
Study of CNS inflammatory demyelinating diseases
This study follows people with certain inflammatory conditions of the brain and spinal cord (like MS, NMOSD, or MOGAD) to learn more about their disease. If you join, you will help researchers understand these conditions better.
Guangzhou, GuangdongAges 18–65 - NCT06551844RecruitingPhase 2
Adaptive platform trial for new dengue treatments
This trial tests different experimental drugs to treat dengue early. It aims to find which treatment works best and is safe for patients who start within 48 hours of fever.
Kuala LumpurAges 10 years+ - NCT06574698Recruiting
Adding Naxitamb to high-risk neuroblastoma treatment
This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.
Guanzhou, GuangdongAges 1–21 - NCT06580574RecruitingPhase 2
Immunotherapy to save the stomach or colon from surgery
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06582654Recruiting
Antibody detection in first-void urine
This study looks at a new way to detect HPV antibodies in a urine sample. It is for people who have received the HPV vaccine to help improve testing.
Edegem, AntwerpAges 9–70 - NCT06584045Recruiting
Testing a bile-based treatment for adult encephalitis
This study tests a natural bile-derived medicine (Calcus Bovis Sativus) to see if it can help adults with new or recent brain inflammation (encephalitis). It focuses on people whose encephalitis is caused by the immune system or a virus, and who have not fully recovered.
Wuhan, HubeiAges 18 years+ - NCT06586177Recruiting
Study on Long-Term Effects of B Cell Therapies for MS
This study looks at how B cell therapies (a type of medicine for MS) create a long-lasting effect in people with relapsing-remitting multiple sclerosis. It aims to understand how these treatments work over time so doctors can better predict benefits and risks.
DüsseldorfAges 18–60 - NCT06586905Recruiting
A study of a new syphilis test at an Ottawa sexual health clinic
This study tests a new rapid syphilis test (Multiplo® Complete Syphilis) that can be done at a clinic. It aims to see how well it detects infectious syphilis compared to standard lab tests. You might help if you are getting syphilis testing at the clinic.
Ottawa, OntarioAges 16 years+ - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT06613490RecruitingEarly Phase 1
CAR NK cells for antibody syndrome and rheumatoid arthritis
This early-phase trial tests whether a new type of immune cell (CAR NK) can treat two conditions: antisynthetase antibody syndrome (a rare autoimmune disease) and rheumatoid arthritis. It's for people whose current treatments haven't worked well enough.
Nanjing, JiangsuAges 18–70 - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT06637865RecruitingPhase 1
Safety study of IMP761 in healthy volunteers
This is a first-in-human study testing the safety of an experimental drug called IMP761. It is an antibody that may affect the immune system. Healthy volunteers aged 18 to 55 can participate to help researchers learn about the drug's safety and how the body processes it.
LeidenAges 18–55 - NCT06668727RecruitingPhase 1
Testing a new antibody for hepatitis B safety
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
Aarhus NAges 18–70 - NCT06676410RecruitingPhase 2
Testing Codivir plus standard HIV treatment in new patients
This trial tests a new investigational drug called Codivir added to standard HIV treatment for people who have never taken HIV medications before. It aims to see if adding Codivir helps control the virus better and is safe.
São PauloAges 18 years+ - NCT07687875RecruitingPhase 1
Virus therapy plus immunotherapy before surgery for rectal cancer
This trial tests a combination of a cancer-killing virus (oncolytic virotherapy) and an immunotherapy drug (pembrolizumab) given before surgery for a certain type of rectal cancer. It aims to see if this approach helps shrink the tumor and improve outcomes for patients whose tumors have a normal DNA repair system (pMMR).
Copenhagen, Captial RegionAges 18 years+ - NCT07573943RecruitingPhase 4
ASC22 with peginterferon to cure chronic hepatitis B
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07686575Recruiting
Ivonescimab with chemo for advanced mouth or throat cancer
This trial tests a new drug, ivonescimab, combined with chemotherapy for people with advanced mouth or throat cancer that can be removed with surgery. The goal is to see if the combination helps shrink tumors before surgery.
Guangzhou, GuangdongAges 18–80 - NCT07403136RecruitingPhase 2
Testing Becotatug Vedotin ± Immunotherapy for advanced esophageal cancer
This trial tests a new targeted drug (Becotatug Vedotin) given either alone or with an immunotherapy drug for people with advanced esophageal squamous cell cancer that has EGFR protein on their tumor cells. The goal is to see if this combination can help when standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT06716450Recruiting
HIV and syphilis self-test study
This study tests a new self-test for HIV and syphilis that you can do yourself at a clinic or community site. It is for people who do not know if they have HIV or syphilis and have not tested positive before.
Victoria, British ColumbiaAges 18 years+
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 542 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.